Trade-Ideas: AMAG Pharmaceuticals (AMAG) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified AMAG Pharmaceuticals (AMAG) as a weak on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

AMAG Pharmaceuticals

(

AMAG

) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified AMAG Pharmaceuticals as such a stock due to the following factors:

  • AMAG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.3 million.
  • AMAG has traded 191,603 shares today.
  • AMAG is trading at 2.00 times the normal volume for the stock at this time of day.
  • AMAG is trading at a new low 3.18% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMAG with the Ticky from Trade-Ideas. See the FREE profile for AMAG NOW at Trade-Ideas

More details on AMAG:

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. AMAG has a PE ratio of 4. Currently there are 5 analysts that rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for AMAG Pharmaceuticals has been 1.4 million shares per day over the past 30 days. AMAG has a market cap of $981.8 million and is part of the health care sector and drugs industry. The stock has a beta of 0.88 and a short float of 25.8% with 5.26 days to cover. Shares are down 30.7% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates AMAG Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and a generally disappointing performance in the stock itself.

Highlights from the ratings report include:

  • AMAG's very impressive revenue growth greatly exceeded the industry average of 13.4%. Since the same quarter one year prior, revenues leaped by 277.1%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • Even though the current debt-to-equity ratio is 1.09, it is still below the industry average, suggesting that this level of debt is acceptable within the Biotechnology industry. Despite the fact that AMAG's debt-to-equity ratio is mixed in its results, the company's quick ratio of 2.05 is high and demonstrates strong liquidity.
  • The share price of AMAG PHARMACEUTICALS INC has not done very well: it is down 17.24% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1511.8% when compared to the same quarter one year ago, falling from $1.46 million to -$20.58 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...